Is Vebreltinib covered by medical insurance?

Vebreltinib (vebreltinib), as an important innovative targeted drug independently developed in my country, has attracted much attention from clinical and patient groups since its launch. Compared with many imported targeted drugs, boricitinib fully combined the genetic characteristics of Chinese tumor patients during its research and development process. It mainly targets patients with MET exon 14 skipping non-small cell lung cancer and specific types of glioma. With the increase in clinical demand, the drug was quickly included in the scope of medical insurance. This is a major progress in the country's popularization of tumor treatment drugs in recent years.

According to the official updated information on the medical insurance catalog, bricitinib enteric-coated capsules have indeed been included in the reimbursement scope of the national medical insurance, and there are clear restrictions on clinical use. The scope of medical insurance payment mainly includes two groups of people: one is patients with locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping; the other is patients with IDH-mutant astrocytoma who have failed previous treatment and have PTPRZ1-MET fusion gene or glioblastoma patients with a low-grade history. This precise delineation not only ensures the rational use of drugs, but also enables medical insurance resources to function more efficiently.

Inclusion in medical insurance is of great significance to the patient group. Previously, the price of bricitinib was high and it was difficult for many families to afford it in the long term. However, the implementation of medical insurance reimbursement has greatly reduced the economic pressure and enabled more patients to obtain continuous and standardized treatment. The medical insurance payment mechanism not only improves drug accessibility at the economic level, but also promotes the implementation of the concept of precision cancer treatment at the social level, allowing more grassroots hospitals and patients to have access to this innovative drug.

With the support of medical insurance policies, the popularity and application scope of bricitinib are expected to continue to expand. For clinicians, the intervention of medical insurance also increases the flexibility of prescriptions, allowing them to choose treatment options more scientifically based on the patient's genetic test results.

Reference materials:https://www.asymbio.com.cn/